Dexmedetomidine and Blood Coagulation

Completed

• Conditions: Blood Coagulation Disorder
• Interventions: Drug: 0.25 ul of dexmedetomidine; Drug: 0.75 ul of dexmedetomidine; Drug: 0 ul of dexmedetomidine; Drug: 0.5 ul of dexmedetomidine

• Registration Number: NCT04269278
• Lead Sponsor: Seoul National University Bundang Hospital

Brief Summary

Dexmedetomidine may alter whole blood coagulation. However, little is known about the dose-response relationships according to the blood concentration of dexmedetomidine. The investigators have therefore performed the present study to measure the effect of dexmedetomidine on the coagulation pathway according to the drug concentration level using a rotational thromboelastometry test.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2020-02-11
• Study First Submitted QC: 2020-02-11
• Study Start: 2020-02-12
• Study First Posted: 2020-02-13
• Primary Completion: 2020-12-30
• Study Completion: 2020-12-30
• Status Verified: 2021-06
• Last Update Submitted: 2021-06-30
• Last Update Posted: 2021-07-02

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 11

Inclusion Criteria

• Healthy volunteers
• Age: 20 to 65 years
• Body weight > 50 kg
• Volunteers who provided informed consent

Exclusion Criteria

• Hematologic disease
• Anticoagulant medication

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
0.5 ng/ml	0.25 ul of dexmedetomidine	Blood specimen which was added 0.25 ul of dexmedetomidine
1.5 ng/ml	0.75 ul of dexmedetomidine	Blood specimen which was added 0.75 ul of dexmedetomidine
0 ng/ml	0 ul of dexmedetomidine	Blood specimen which was added 0 ul of dexmedetomidine
1.0 ng/ml	0.5 ul of dexmedetomidine	Blood specimen which was added 0.5 ul of dexmedetomidine

Primary Outcome Measures

Name	Time	Method
FIBTEM	During the rotational thromboelastometry analysis/ an average of 1 hour	Fibrinolytic pathway values of rotational thromboelastometry analysis/ FIBTEM is not an acronym.

Secondary Outcome Measures

Name	Time	Method
EXTEM	During the rotational thromboelastometry analysis/ an average of 1 hour	Extrinsic pathway values of rotational thromboelastometry analysis/ EXTEM is not an acronym.
INTEM	During the rotational thromboelastometry analysis/ an average of 1 hour	Intrinsic pathway values of rotational thromboelastometry analysis/ INTEM is not an acronym.

Trial Locations

Locations (1)

Seoul National University Bundang Hospital; 🇰🇷 Seongnam-si, Gyeonggi-do, Korea, Republic of